项目名称: 智能响应型纳米囊介导的针对双免疫检查点的肿瘤分子靶向免疫基因治疗
项目编号: No.31670948
项目类型: 面上项目
立项/批准年度: 2017
项目学科: 生物科学
项目作者: 刘兰霞
作者单位: 中国医学科学院
项目金额: 25万元
中文摘要: 肿瘤治疗方法繁多,其中通过解除肿瘤免疫耐受、激活机体自身免疫系统清除肿瘤细胞是一个极具潜力的治疗手段。大量研究均报道了联合应用针对免疫检查点CTLA-4和PD-1的抗体治疗多种类型的肿瘤疗效显著。本课题组在前期研究中设计合成了具有氧化还原刺激响应性的聚乳酸-S-S-聚乙二醇两亲性嵌段聚合物,并以此为自组装基元制备得到了具有疏水性囊壁和亲水性囊腔的智能响应型纳米囊。本项目提出构建携带CTLA-4apt和PD-1siRNA的智能响应型纳米囊,既可通过纳米囊表面的CTLA-4apt实现对纳米囊的靶向递送和产生类似CTLA-4抗体治疗的作用,又可通过包载PD-1siRNA,利用纳米囊的智能响应性实现siRNA胞浆递送,在mRNA水平上发挥干扰PD-1合成的作用,以此达到在同一个靶细胞上同时抑制两个免疫检查点的目的,实现叠加和协同效应,以最大限度的解除肿瘤免疫抑制、激活机体对肿瘤的识别和杀伤作用。
中文关键词: 免疫检查点;肿瘤免疫治疗;基因治疗;纳米囊;核酸适配体
英文摘要: Relieving immune tolerance via activation of the immune system, which kills tumor cells, is a promising tumor immunotherapy method. We have developed a redox responsive PDLLA-S-S-PEG nanocapsule previously. In this project, we are aiming to engineer an anti-cancer delivery system based on the PDLLA-S-S-PEG nanocapsule by conjugating the CTLA-4 aptamer to its surface while encapsulating a PD-1siRNA within its hydrophilic cavity. The CTLA-4 aptamer will subsequently facilitate CTLA-4 binding, tumor targeting and inhibit CTLA-4 activity, whilst the PD-1siRNA could ideally block the PD-1 pathway after cytoplasm release of the siRNA and interrupt the PD-1 mRNA synthesis. Thus, this nanocapsule-based delivery system could combine the both anti-CTLA-4 and PD-1 anti-tumor therapies by targeting both checkpoints on the same T cells, and activate the the cytotoxic effect of T cells against tumor cells.
英文关键词: Immune checkpoint;Tumor immune therapy;Gene therapy;Nanocapsules;Aptamer